After a radical downsizing, Teva beefs up US R&D campus; Tiaki recruits Suzanne Bruhn for the helm
→ Eighteen months after setting in motion a draconian reorganization aimed at shuttering facilities and laying off 14,000 staffers, Teva says it is adding to its footprint at their US R&D center in West Chester, PA. The pharma company says it’s snapped up 3 buildings in the office park on Brandywine Parkway for its North American R&D HQ, where they’re focused on biologics development and manufacturing. By the end of this year Teva says that they’ll have a staff of 650 on their campus occupying 6 buildings and 314,000 square feet of space.
→ Cambridge, MA-based Tiaki Therapeutics has recruited Suzanne L. Bruhn as its new CEO. She takes over from interim CEO Barbara Tate, the chief strategy officer of the Dementia Discovery Fund. Her last post was as CEO of Proclara. Tiaki has targeted immune cells of the brain — microglia — in an attempt to address inflammatory-driven CNS disorders and protect cognitive function.
→ Japan’s Ono Pharmaceuticals has struck an Asian licensing deal for Forty Seven’s anti-CD47 drug 5F9. Ono gets rights to the drug for Japan, South Korea, Taiwan and the ASEAN countries in exchange for $15.8 million in cash and up to $104 million in milestones.